Canopy Growth Corp (WEED)

Currency in CAD
42.80
+0.29(+0.68%)
Closed·
Showing Canopy Growth historical data. For real-time data please try another search
Day's Range
42.1443.16
52 wk Range
1.1843.16
Key Statistics
Prev. Close
42.8
Open
42.23
Day's Range
42.14-43.16
52 wk Range
1.18-1.26
Volume
558.28K
Average Volume (3m)
6.89M
1-Year Change
3,379.67%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Canopy Growth Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Canopy Growth Corp Company Profile

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works. The company offers dried flower and pre-rolled joints; extracts and concentrates, such as softgel capsules; cannabis edibles, including gummies; cannabis vapes; and oils, beverages, concentrates. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Wana, and Claybourne brands, as well as DOJA, LivRelief, Ace Valley, and Vert brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

Employees
960
Market
Canada

Canopy Growth Corp Earnings Call Summary for Q4/2025

  • Adjusted EBITDA loss reduced to $9M in Q4 2025, down from $15M last year; free cash flow outflow improved by $109M year-over-year
  • Net revenue fell short of expectations; Canadian medical cannabis market facing mid-single-digit decline
  • Company targeting $20M in annual cost reductions; focusing on achieving positive adjusted EBITDA
  • New Storz & Bickel device launch planned for fall 2025; expecting growth in European medical markets
  • Stock trades at $1.37, down from 52-week high of $9.92; market cap at $217.5M with LTM EBITDA of -$35.19M
Last Updated: 30/05/2025, 16:20
Read Full Transcript

Analyst Ratings

1 Buy
4 Hold
2 Sell
Ratings:
7 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 0.00

Earnings

Latest Release
May 30, 2025
EPS / Forecast
-1.44 / --
Revenue / Forecast
65.03M / --
EPS Revisions
Last 90 days

WEED Income Statement

People Also Watch

60.85
MP
+0.98%
77.51
BNS
+0.53%
32.58
BCE
-0.12%
102.89
CRWV
-5.38%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.